Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs FINGOLIMOD HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Reduction of risk of hospitalization and all-cause mortality in COVID-19 (EUA, no longer authorized)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
0.5 mg orally once daily
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily metabolized by cytochrome P450 4F2 (CYP4F2) via omega-hydroxylation; also undergoes hydrolysis by non-CYP enzymes. Minor contribution from CYP3A4.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
>99.7% bound to plasma proteins, primarily albumin and lipoproteins.
4-6 L/kg; large Vd indicates extensive tissue distribution
Approximately 1700 L (17 ± 6 L/kg) indicating extensive distribution into tissues, including erythrocytes, brain, and adipose tissue.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral bioavailability is approximately 93% (range 80–100%).
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required for GFR ≥15 m L/min. Fingolimod has not been studied in ESRD (GFR <15 m L/min) or dialysis; use caution.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh A or B: No dose adjustment. Child-Pugh C: Contraindicated.
Not approved for pediatric patients <18 years; safety and efficacy not established.
For patients ≥10 years and >40 kg: 0.5 mg orally once daily. For patients <40 kg or <10 years: Safety and efficacy not established.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment; use caution due to increased risk of bradycardia, infections, and comorbidities.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Increased risk of serious infections, including life-threatening opportunistic infections such as progressive multifocal leukoencephalopathy (PML), cryptococcal meningitis, and herpes virus infections. Baseline and periodic monitoring required.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Risk of bradyarrhythmia and atrioventricular block at treatment initiation; require ECG monitoring. Macular edema, especially in patients with uveitis or diabetes. Reduced pulmonary function; avoid in severe respiratory disease. Posterior reversible encephalopathy syndrome (PRES). Hepatic injury; monitor liver enzymes. Fetal harm; effective contraception required. Increased risk of infections; withhold during serious infection. Avoid live vaccines during and for 2 months after treatment.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to fingolimod or any component. Recent (within 6 months) myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, or NYHA class III/IV heart failure. History of Mobitz type II 2nd-degree or 3rd-degree AV block or sick sinus syndrome unless pacemaker in place. Severe untreated sleep apnea. Baseline prolonged QTc interval (>500 msec) or concurrent Class Ia or Class III antiarrhythmic drugs.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Grapefruit and grapefruit juice increase fingolimod exposure by inhibiting CYP3A4 and CYP4F2; avoid concurrent consumption.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and increased resorptions. In humans, S1P receptor modulators are associated with a 2-fold increase in major congenital malformations when exposed in the first trimester. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and growth restriction due to maternal lymphopenia and immune modulation.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Unknown if excreted in human breast milk. M/P ratio not established. Due to potential for serious adverse reactions in breastfed infants (e.g., immunosuppression), advise against breastfeeding during therapy and for 2 months after last dose.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dose adjustments established for pregnancy; however, pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Fingolimod is contraindicated in pregnancy due to fetal risk; use only if benefit justifies risk. Discontinue at least 2 months before planned conception due to long half-life (6-9 days).
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
First-dose monitoring required for 6 hours post-initial dose due to bradycardia risk; obtain baseline ECG, blood pressure, and heart rate. Avoid use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias. Vaccinate against varicella zoster virus (VZV) before initiation if no history of chickenpox or vaccination. Monitor for macular edema, especially in patients with diabetes or uveitis. Lymphopenia is expected; do not discontinue for low lymphocyte counts unless infection occurs.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take exactly as prescribed; do not stop without consulting your doctor.,You will be observed for at least 6 hours after your first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) immediately.,Report any vision changes, such as blurriness or blind spots.,Avoid live vaccines while taking this medication and for 2 months after stopping.,Fingolimod can harm a fetus; use effective contraception during treatment and for 2 months after stopping.,Avoid grapefruit and grapefruit juice as they may increase side effects.
No interactions on record
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs FINGOLIMOD HYDROCHLORIDE, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. FINGOLIMOD HYDROCHLORIDE is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and FINGOLIMOD HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of FINGOLIMOD HYDROCHLORIDE is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and FINGOLIMOD HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. FINGOLIMOD HYDROCHLORIDE is classified as Category C. First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and inc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.